巴西批准新的前列腺癌成像剂Illuccix,这是拉丁美洲的首例。 Brazil approves new prostate cancer imaging agent Illuccix®, a first for Latin America.

巴西的卫生监管机构已经批准了Illuccix,这是前列腺癌的新成像剂,是拉丁美洲首次批准。 Brazil's health regulator has approved Illuccix®, a new imaging agent for prostate cancer, marking the first such approval in Latin America. 该制剂使用高级成像检测前列腺癌细胞,有可能改进诊断和患者结果。 The agent uses advanced imaging to detect prostate cancer cells, potentially improving diagnostics and patient outcomes. 这项批准支持Telix制药公司与R2PHARMA的合资企业在巴西分发类似的癌症治疗工具,预计巴西放射药物市场在未来十年将增长到3.3亿美元。 The approval supports Telix Pharmaceuticals' joint venture with R2PHARMA to distribute similar cancer treatment tools in Brazil, where the market for radiopharmaceuticals is projected to grow to $330 million in the next decade.